|
PAVE 100 is a planned test-of-concept efficacy trial of an AIDS vaccine developed by the Vaccine Research Center (VRC) at the US National Institutes of Health. The original version of PAVE 100 was scheduled to take place in eastern and southern Africa and in the Americas. Screening for enrollment in the Americas was scheduled to start in September 2007. This was put on hold after the release of disappointing data from the STEP vaccine study of Merck’s MRK-AD5 vaccine.
(For more information on STEP visit www.avac.org/step.htm.)
There has been significant debate and discussion about how to redesign the PAVE 100 protocol in light of the STEP data. The documents AVAC has developed (linked below) are designed to help advocates, community groups and other stakeholders understand some of the key questions that have been raised in discussions about PAVE 100.
*******************
Making sense of the PAVE 100 debate: A tool for HIV prevention advocates
This document is designed to help advocates, community groups and other stakeholders understand some of the key questions that have been raised in discussions about PAVE 100. This is a "living" document and will be updated as the discussion evolves.
- Making sense of the PAVE 100 debate: In Brief
This one-pager is designed to give advocates a quick look at the issues and key questions raised in discussions about PAVE 100.
Disponible en español abajo.
Disponível no português abaixo.
- Comprendamos el debate en torno al PAVE 100: Una herramienta para los grupos de tareas que trabajan en la prevención del VIH
- Comprendamos el debate en torno al PAVE 100: En Breve
- Entendendo o debate sobre a PAVE 100: Uma ferramenta para os defensores
da prevenção ao HIV
- Entendendo o debate sobre a PAVE 100: No sumário
Treatment Action Group (TAG) Position Statement on the Proposed PAVE 100A
Vaccine Trial (30 May 2008)
Community HIV/AIDS Mobilization Project (CHAMP) comments on PAVE 100A trial
(29 May 2008)
This website Copyright 2006 AIDS Vaccine Advocacy Coalition
Site Design: Canfield Design Studios, Inc.
|
